In this article, we will discuss the 10 stocks whose price targets were recently raised by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets.
05. Cintas Corporation (NASDAQ:CTAS)
Upside Potential: 13%
On March 28, Truist Securities revised its outlook on Cintas Corporation (NASDAQ:CTAS), a prominent player in the uniform and business services industry. They raised the price target for Cintas Corporation (NASDAQ:CTAS) from $660 to $775 while maintaining a buy rating on the stock. This upward adjustment indicates a 13% upside potential compared to the stock’s current market price of $660.00 as of April 1. Cintas Corporation (NASDAQ:CTAS) operates within the broader business services sector, providing specialized products and services such as uniforms, restroom supplies, safety products, and facility services to businesses across various industries. Truist Securities pointed out Cintas Corporation (NASDAQ:CTAS) commitment to innovation and technology adoption, which positions the company to capitalize on emerging opportunities and stay ahead of competitors in the rapidly evolving business services landscape. Overall, Truist Securities’ bullish stance on Cintas reflects their confidence in the company’s ability to deliver sustained growth and generate value for shareholders over the long term. The upward revision in the price target signifies their optimistic assessment of Cintas Corporation (NASDAQ:CTAS) fundamentals and future prospects, making it an attractive investment opportunity for investors seeking exposure to the business services sector.
04. The Walt Disney Company (NYSE:DIS)
Upside Potential: 19%
On March 28, Needham, a leading financial services firm, adjusted its outlook on The Walt Disney Company (NYSE:DIS), a major player in the entertainment and media industry. They increased the price target for The Walt Disney Company (NYSE:DIS) from $120.00 to $145.00 while reaffirming a buy rating on the stock. This upward revision indicates a significant 19% upside potential compared to the stock’s current market price of $121.11 as of April 1. The Walt Disney Company (NYSE:DIS) operates within the broader entertainment and media sector, encompassing segments such as theme parks, media networks, studio entertainment, and direct-to-consumer streaming services. Needham’s decision to raise the price target and maintain a buy rating reflects their positive assessment of The Walt Disney Company (NYSE:DIS) future growth prospects and overall performance within the entertainment industry. Needham’s bullish stance on The Walt Disney Company (NYSE:DIS) reflects their confidence in the company’s ability to navigate challenges and capitalize on opportunities in the rapidly evolving entertainment landscape. The upward adjustment in the price target signifies their optimistic outlook for Disney’s long-term growth potential, making it an attractive investment opportunity for investors seeking exposure to the entertainment and media industry.
03. DraftKings Inc. (NASDAQ:DKNG)
Upside Potential: 22%
02. Wayfair Inc. (NYSE:W)
Upside Potential: 27%
01. Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Upside Potential: 38%
On March 28, Mizuho, a prominent financial institution, increased its price target on Axsome Therapeutics, Inc. (NASDAQ:AXSM), a key player in the pharmaceutical industry. Despite the minimal adjustment from $108.00 to $109.00, they upheld their Buy rating for the company. This adjustment implies a significant 38% upside potential compared to the stock’s current market price of $77.55 as of April 1. Axsome Therapeutics, Inc. (NASDAQ:AXSM) operates in the highly competitive and dynamic pharmaceutical sector, focusing on the development of innovative therapies to address unmet medical needs in various therapeutic areas. Mizuho’s decision to maintain a Buy rating and slightly increase the price target reflects their confidence in Axsome Therapeutics, Inc. (NASDAQ:AXSM) continued growth prospects and potential for value creation for investors. Mizuho’s reaffirmation of a Buy rating and modest increase in the price target for Axsome Therapeutics, Inc. (NASDAQ:AXSM) reflect their positive assessment of the company’s innovative pipeline, strategic partnerships, financial strength, and execution capabilities within the competitive pharmaceutical industry. The upward adjustment in the price target signals Mizuho’s confidence in Axsome Therapeutics, Inc. (NASDAQ:AXSM) potential to deliver value for investors in the coming months and years.
Should you invest $1,000 in Axsome Therapeutics right now?
Before you buy stock in AXSM, consider this:
The Insider Monkey Quarterly Newsletter just identified what we believe are the 14 best stocks for investors to buy now… and AXSM wasn’t one of them. The 14 stocks that made the cut could produce monster returns in the next few months.
Quarterly Newsletter is your easy-to-follow blueprint for building a winning portfolio. It includes stock picks from billionaires, regular updates from hedge fund investor letters, and 14 fresh stock picks each quarter. The Quarterly Newsletter service has more than doubled the return of S&P 500 since 2014.
You can also take a peek at Top 20 Most Unfriendly States in the US and 13 Most Profitable Renewable Energy Stocks.